A #phase2trial has shown promising protective efficacy for what could become the first #vaccine against #hookworm, a #parasiticdisease affecting hundreds of millions of people around the world.

pharmaphorum.com/news/hope-ri...

[ALA Client News] Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate

ala.associates/funding/axol...

#ALS #funding #phase2trial

ProKidney stock soars after positive Phase 2 trial results Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock surged 115% after the company reported statistically significant and clinically meaningful positive topline results from its Phase 2 REGEN-007 trial evaluating rilparencel in patients with chronic kidney disease (CKD) and diabetes. The late clinical-stage cellular therapeutics company announced that patients in Group 1 of the trial showed a 78% improvement in annual kidney function decline following treatment. The annual decline in estimated glomerular filtration rate (eGFR) slope improved from -5.8 mL/min/1.73m² in the pre-injection period to -1.3 mL/min/1.73m² after the last rilparencel injection, representing a statistically significant difference of 4.6 mL/min/1.73m² per year. Group 2, which tested an exploratory dosing regimen, showed a 50% improvement in kidney function decline, suggesting evidence of a dose response, though this difference was not statistically significant. The REGEN-007 trial evaluated 49 patients who received at least one rilparencel injection across two treatment groups. Group 1 replicated the dosing schedule of the company’s ongoing Phase 3 PROACT 1 study, with patients receiving two scheduled injections approximately three months apart. "We are very encouraged by the REGEN-007 topline results that demonstrated a robust improvement in eGFR slope following treatment with rilparencel in Group 1 as well as evidence of a dose response in Group 2," said Bruce Culleton, M.D., CEO of ProKidney. No rilparencel-related serious adverse events were observed in the study, with the safety profile consistent with previously reported results and comparable to a kidney biopsy. The company plans to submit the full results from REGEN-007 to the American Society of Nephrology’s 2025 Kidney Week as a late-breaking clinical trial. ProKidney is also preparing for an upcoming FDA Type B meeting to confirm its approach to eGFR slope as a surrogate endpoint for accelerated approval. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if PROK is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #ProKidney #StockMarket #Investing #Phase2Trial #HealthcareStocks

Psilocybin, a psychedelic compound from mushrooms, benefits cancer patients with major depression – BioNews Central A phase 2 trial reveals that a single dose of psilocybin offers long-term relief from symptoms of depression and anxiety in cancer patients. ...

A #Phase2Trial reveals that a single dose of #psilocybin offers long-term relief from symptoms of #depression and #anxiety in #CancerPatients.

Click Subscribe #TourmalineBio #Phase2Trial #Investing #StockMarket #ClinicalTrials